Hosted on MSN
Disc Medicine stock slides after FDA fast-track approval doubts surface — Wall Street calls it an 'overreaction'
・Disc Medicine management said earlier this month that its application seeking approval for Bitopertin has officially been accepted for review on schedule. ・Wall Street analysts dismissed the media ...
Twin Disc reported Q1 sales of $80.0 million, representing a 9.7% increase year-over-year, in line with market expectations. Organic sales growth was more modest at 1.1%, with the recent Kobelt ...
Twin Disc Q3 FY25 slides: Sales up 9.5% while EPS turns negative amid mixed segment results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback